PPP2R1A mutations are common in the serous type of endometrial cancer.
about
LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potentialSilencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility.Mapping the human phosphatome on growth pathways.Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.The genomics and genetics of endometrial cancer.Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression.PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in CancerPatient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathwayTargeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Ornithine decarboxylase as a therapeutic target for endometrial cancer.Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.Next-Generation Sequencing.Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too LateCancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis
P2860
Q54608378-C15D6EFD-7C5C-476E-BD0C-602A6A331913Q54608381-E7EB9E25-82B5-4533-8E2E-F1EB60181462Q54608385-50E00FB8-94CD-484A-B186-FCFD657F6CB8Q54608393-657B9437-A738-487C-8CD1-ED4DCF8FE703Q54608395-4BE1068B-FDC7-482B-9777-9B0E82B34378Q54608400-94FF5D1D-C550-4EC9-A988-6F84BE0AE306Q54608402-4A8DE5A4-CBAF-45EF-9BC3-9D8300EE2C7AQ54608403-2AC01636-85AA-462C-87F8-904AA8EAE0C6Q54608409-A8D6950A-BEFC-46D4-B0EB-9F1E385D1CEAQ54608411-0B57B59B-57B9-489A-B1FF-85A92F638044Q54608515-AEA01FF3-EE8B-45BA-BFB6-E3A6952FE5A4Q54907755-66CA742E-0945-430F-B1FF-2F4FF320545CQ54907756-DD950282-2E9A-4E9B-9D91-8AAE0DD9AF5C
P1343
Q26865711-48FD0BD5-DD36-4A4F-A0DB-EFFC1504869AQ30412034-CCF73A95-9110-497D-82EE-80D55712C710Q34294009-EFF310A2-2262-4004-AC58-3D4AE770310AQ34330600-0BA9EE97-6B20-410E-836D-30CF4F21723EQ35132338-1CAD5127-1B7E-4F97-88E8-172D19657EDEQ36151896-2A3FA93D-F811-4AAB-9510-624365142246Q36272766-4E919487-6F19-4BDE-81F7-C422FFD4D215Q36796453-F258DE3B-4DAD-4443-9F3E-3BB04D55F5A9Q36974742-18FF4BA2-8940-4F02-9446-9B5BD14D022EQ37699264-A77D5EF7-AA76-4AFA-98A7-47EB78972E61Q38617799-3FACFDED-668E-4B27-84C8-028DF3E62568Q46636207-85E03AAF-332E-4B62-8DFD-E75E0217EDFAQ50000289-119AE827-2F81-4EED-8F35-CCD423BFF3B8Q51032285-13339B94-A036-4A0D-A838-B5A521C739E5Q51609445-26A83859-20D4-4310-B61C-CCD2CA24974BQ57169683-4D381035-DB26-43D9-A308-747D4C6A1983Q58129865-10666459-3865-401B-AB66-277CAC2848FE
P2860
PPP2R1A mutations are common in the serous type of endometrial cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
PPP2R1A mutations are common in the serous type of endometrial cancer.
@en
PPP2R1A mutations are common in the serous type of endometrial cancer.
@nl
type
label
PPP2R1A mutations are common in the serous type of endometrial cancer.
@en
PPP2R1A mutations are common in the serous type of endometrial cancer.
@nl
prefLabel
PPP2R1A mutations are common in the serous type of endometrial cancer.
@en
PPP2R1A mutations are common in the serous type of endometrial cancer.
@nl
P2093
P2860
P4510
P356
P1476
PPP2R1A mutations are common in the serous type of endometrial cancer.
@en
P2093
Deepak C Nagendra
G Larry Maxwell
James Burke
John I Risinger
P2860
P304
P356
10.1002/MC.20850
P577
2011-08-31T00:00:00Z